461030.KQ IMB Dx, Inc.
- Market cap
- KRW 34.3B
- P/E
- -
- P/B
- 1.47x
- ROE
- -28.4%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 461030.KQ undervalued?
Graham numberThe Graham number of IMB Dx, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IMB Dx, Inc. fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-28.4%), below 10%.
ROA 0/1
Return on assets (-26.8%) is below the industry median (-10.2%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (17.2%) is below the industry median (46.9%).
Revenue Growth 2/2
Revenue grew 26.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.5 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.5x) is below the industry median (1.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
IMB Dx, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IMB Dx, Inc.
IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The comp…
Full company profileIMB Dx, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IMB Dx, Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.23B | 2.62B | 4.03B | 3.41B | 5.33B | 5.57B |
| Gross Profit | 31.6M | 372M | 1.42B | 888M | 1.39B | 2.13B |
| Operating Income | -5.28B | -8.67B | -7.77B | -10.6B | -8.66B | -7.73B |
| EBITDA | - | -7.59B | -7.82B | -7.95B | -6.48B | -6.06B |
| Net Income | -9.79B | -10.4B | -10.4B | -9.58B | -7.93B | -6.62B |
| EPS | -700 | -746 | -744 | -683 | -566 | -461 |
| Balance Sheet | ||||||
| Total Assets | 24.0B | 17.4B | 9.82B | 34.0B | 27.1B | 24.6B |
| Total Liabilities | 46.4B | 48.5B | 1.50B | 1.59B | 1.96B | 1.33B |
| Shareholders' Equity | -22.3B | -31.1B | 8.32B | 32.5B | 25.2B | 23.3B |
| Cash & Short-term Investments | 19.3B | 11.4B | 4.36B | 28.6B | 2.08B | 11.5B |
| Cash Flow | ||||||
| Operating Cash Flow | -4.01B | -6.33B | -6.23B | -6.65B | -6.20B | -7.89B |
| Capital Expenditure | 1.08B | 1.75B | 504M | 908M | 1.00B | 10.0M |
| Free Cash Flow | -5.10B | -8.07B | -6.74B | -7.55B | -7.20B | -7.90B |
| Ratios | ||||||
| ROE | - | - | -125.2% | -29.5% | -31.5% | -28.4% |
| ROA | -40.7% | -60.2% | -106.1% | -28.1% | -29.3% | -26.8% |
| Net Profit Margin | -795.6% | -397.6% | -258.7% | -281.1% | -148.9% | -118.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
IMB Dx, Inc. dividends
IMB Dx, Inc. has not paid dividends in the last 5 fiscal years.
Who owns IMB Dx, Inc.
- Insiders 46.02%
- Institutions 0.00%
- Public & others 53.99%
- Shares outstanding 14.3M
- Free float 7.10M
IMB Dx, Inc. company profile
- Company name
- IMB Dx, Inc.
- Ticker
- 461030.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Fiscal year end
- December
- Address
- BYC Highcity Bldg A, Seoul, South Korea
- Phone
- 82 2 6951 2906
- Website
- imbdx.com
About IMB Dx, Inc.
IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. IMB Dx, Inc. was founded in 2018 and is based in Seoul, South Korea.
IMB Dx, Inc. management
7- Mr. Tae-You Kim M.D., Ph.D.Co-Founder & CEO · born 1961
- Du-hee Bang Ph.D.Co-Founder & Chief Scientific Advisor
- Peter Moon M.B.A.Co-Founder & Sales Executive Advisor
- Mr. Siyeon KimChief Operating Officer · born 1965
- Sang-Hyun Song Ph.D.Chief Scientific Officer
- Mr. Hwang-Phill Kim Ph.D.Chief Business Officer · born 1975
- Yongjun Cha M.D.Chief Medical Advisor